Day One Biopharmaceuticals (DAWN) News Today

HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Friday.

Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 6.1%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 20,000 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $16.01, for a total transaction of $320,200.00. Following the completion of the sale, the insider now owns 1,121,081 shares of the company's stock, valued at $17,948,506.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Atlas Venture Life Science Advisors LLC lowered its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 15.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,430,257 shares of the company's stock a

Piper Sandler reiterated an "overweight" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday.

Wellington Management Group LLP boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 77.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 208,969 shares of the company's stock after acquir

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have gi

Goldman Sachs Group Inc. boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 28.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,118,849 shares of the company's stock after buyi

HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday.

Needham & Company LLC reaffirmed a "buy" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday.

Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 9.7% Higher

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.4%

PFM Health Sciences LP decreased its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 41.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,303,575 shares of the company's

Braidwell LP raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 13.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,215,573 shares of the company's

Superstring Capital Management LP acquired a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 379,626 shares of the company's stock, valued at approximately $5,543,000.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have ass

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the target of a large drop in short interest in May. As of May 15th, there was short interest totalling 10,600,000 shares, a drop of 5.3% from the April 30th total of 11,190,000 shares. Approximately 17.5% of the company's stock are short sold. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is currently 9.7 days.

Franklin Resources Inc. boosted its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 4.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,236,795 shares of the company's stock after purchasing an ad

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 6.4%

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 2,267 shares of the business's stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $16.08, for a total value of $36,453.36. Following the completion of the sale, the insider now directly owns 1,171,081 shares of the company's stock, valued at approximately $18,830,982.48. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Nicholas Investment Partners LP lessened its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 86.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 303,318 shares of the company's stock after selling 1,

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at Wedbush dropped their Q2 2024 earnings per share estimates for Day One Biopharmaceuticals in a research note issued on Tuesday, May 7th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Analysts at Wedbush reduced their FY2027 earnings per share estimates for shares of Day One Biopharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Wedbush analyst R. Driscoll now expects that the

TimesSquare Capital Management LLC raised its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 45.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,666,065 shares of the company's stock after

Wedbush reaffirmed an "outperform" rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday.

HC Wainwright decreased their target price on Day One Biopharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Tuesday.

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down After Insider Selling

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) CFO Charles N. York II sold 8,078 shares of Day One Biopharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $144,192.30. Following the completion of the transaction, the chief financial officer now owns 217,293 shares of the company's stock, valued at $3,878,680.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High at $17.87

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 5.2%

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 10.9%